Cingulate (CINGW) Cash from Operations (2021 - 2025)
Cingulate's (CINGW) quarterly Cash from Operations came in at -$3.6 million in Q4 2025, up 11.82% on a YoY basis from -$3.2 million in Q4 2024, and up 15.25% quarter-over-quarter from -$4.2 million in Q3 2025.
Analysis
Cingulate (CINGW) Cash from Operations (2021 - 2025) Analysis & Trends
Cingulate (CINGW) has reported Cash from Operations for 5 consecutive years, with -$3.6 million the latest figure, recorded in Q4 2025.
- For the quarter ending Q4 2025, Cash from Operations rose 11.82% year-over-year to -$3.6 million; the trailing twelve-month figure through Dec 2025 stood at -$17.2 million (up 6.54% YoY), and the FY2025 full-year result was -$17.2 million, up 6.54% from the prior year.
- Cash from Operations grew to -$3.6 million in Q4 2025 per CINGW's latest filing, from -$4.2 million in the prior quarter.
- Across five years, Cash from Operations topped out at -$1.6 million in Q2 2021 and bottomed at -$8.7 million in Q1 2024.
- Historically, Cash from Operations has averaged -$3.9 million across 5 years, with a median of -$4.0 million in 2024.
- The sharpest annual moves came in 2022 and 2024: Cash from Operations slumped 184.53% in 2022, then jumped 62.16% in 2024.
- Over 5 years, Cash from Operations stood at -$4.6 million in 2021, then rose by 9.0% to -$4.2 million in 2022, then jumped by 39.09% to -$2.6 million in 2023, then sank by 59.21% to -$4.1 million in 2024, then advanced by 11.82% to -$3.6 million in 2025.
- According to Business Quant data, Cash from Operations over the past three periods registered -$3.6 million, -$4.2 million, and -$4.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 644.46 Bn | 623.70 Bn | 17.26 Bn | 8.62 Bn |
| 2 | AbbVie | 440.11 Bn | 433.54 Bn | 12.70 Bn | 3.44 Bn |
| 3 | Merck | 365.04 Bn | 357.90 Bn | 12.21 Bn | 5.37 Bn |
| 4 | Novartis Ag | 266.82 Bn | 259.13 Bn | 11.24 Bn | 5.88 Bn |
| 5 | Pfizer | 159.14 Bn | 147.45 Bn | 10.94 Bn | 835.00 Mn |
| 6 | Sanofi | 52.47 Bn | 45.09 Bn | 10.79 Bn | 3.44 Bn |
| 7 | Revolution Medicines | 44.26 Bn | 44.26 Bn | - | -387.32 Mn |
| 8 | Incyte | 25.32 Bn | 20.79 Bn | 1.57 Bn | 507.66 Mn |
| 9 | United Therapeutics | 21.46 Bn | 18.80 Bn | 683.80 Mn | 313.60 Mn |
| 10 | Cingulate | 100,214.03 | 100,214.03 | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -3.60 Mn |
| Sep 30, 2025 | -4.24 Mn |
| Jun 30, 2025 | -4.80 Mn |
| Mar 31, 2025 | -4.61 Mn |
| Dec 31, 2024 | -4.08 Mn |
| Sep 30, 2024 | -3.88 Mn |
| Jun 30, 2024 | -1.74 Mn |
| Mar 31, 2024 | -8.75 Mn |
| Dec 31, 2023 | -2.56 Mn |
| Sep 30, 2023 | -4.29 Mn |
| Jun 30, 2023 | -4.60 Mn |
| Mar 31, 2023 | -3.58 Mn |
| Dec 31, 2022 | -4.21 Mn |
| Sep 30, 2022 | -3.40 Mn |
| Jun 30, 2022 | -4.41 Mn |
| Mar 31, 2022 | -3.86 Mn |
| Dec 31, 2021 | -4.62 Mn |
| Sep 30, 2021 | -2.59 Mn |
| Jun 30, 2021 | -1.55 Mn |
| Mar 31, 2021 | -1.67 Mn |